- 询价
- 辰辉创聚生物
- 中国
- NBAB-105254
- 2025年07月10日
- ELISA
- Mouse
企业认证
相关产品推荐更多 >
Luteinizing Hormone-Releasing Hormone (LHRH) Polyclonal Antibody抗体 | Anti-Luteinizing Hormone-Releasing Hormone (LHRH) Polyclonal Antibody
询价
CD44抗体| Anti-CD44 Monoclonal Antibody
询价
CD69抗体 | Anti-CD69 Polyclonal Antibody
询价
RON/MSP receptor (PE)抗体 | Anti-RON/MSP receptor Monoclonal Antibody (PE)
询价
IL-21抗体 | Anti-IL-21 Polyclonal Antibody
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Mouse Coagulation Factor IX / FIX / F9 protein
- 亚型：
Polyclonal Rabbit IgG
- 保存条件：
This liquid antibody can be stored at 2℃-5136℃ for at least two weeks. Avoid repeated freeze/thaw cycles.
- 克隆性：
多克隆
- 适应物种：
Mouse
- 保质期：
see COA
- 库存：
大量
- 供应商：
辰辉创聚生物
- 应用范围：
ELISA
- 靶点：
Factor IX
- 抗体英文名：
Factor IX antibody
- 抗体名：
Factor IX抗体
- 规格：
100ug;500ug;1mg
| 产品信息
品名:NebuSelect™ Anti-Factor IX Polyclonal Antibody
货号:NBAB-105254
品牌:Nebulabio
规格:100ug;500ug;1mg
| 产品描述
| 产品属性
Product Category：Rabbit PAb
Reactivity：Mouse
Specificity：Mouse Factor IX
Immunogen：Recombinant Mouse Coagulation Factor IX / FIX / F9 protein
Isotype：Polyclonal Rabbit IgG
Purification：Protein A
Buffer：0.2 μm filtered solution in PBS
Conjugate：Unconjugated
Applications：ELISA
Dilution：ELISA: 1:1000-1:2000
Storage：Store at 4°C for short-term, -20°C for long-term. Avoid repeated freezing and thawing cycles.
For Research Use Only!
To get more information, please contact us freely.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Factor IX Gene Therapy for Hemophilia
Using gene therapy to produce systemic levels of human factor IX for the treatment of hemophilia B has been clinically evaluated using viral-based vectors. The efficacy of this approach has been limited because of immune responses
Ex Vivo Stromal Cell Electroporation of Factor IX cDNA for Treatment of Hemophilia B
Hemophilia B is an X-linked genetic disorder that typically results from chronic circulating deficiency of blood coagulation factor IX (FIX) (1). While the occurrence of hemophilia B is significantly less frequent than hemophilia A (factor
Identification of Mutations in the Human Factor VII Gene
It has been recognized from the early 1800s that activation of coagulation can be initiated by the exposure of subendothelial layers (tissue factor), but it was the 1940s before factor VII (FVII) was included in this event
技术资料暂无技术资料 索取技术资料
